● In Stock
Selank
≥99% Purity | HPLC Verified
$30.00
PASSED
Sterility & Endotoxins
PASSED
Net Content & Purity
Purity:
≥99%
Store at
-20°C
Synthetic tuftsin-derived heptapeptide approved in Russia for GAD, studied for anxiolytic and nootropic effects. Research use only.
| Strength | 5mg |
| molecular_formula | C33H57N11O9 |
| Molecular Weight | 751.87 g/mol |
| Purity | >99% (HPLC) |
| Form | Lyophilized Powder |
85%
Anxiolytic Efficacy
Comparable to benzodiazepine (83%) in RCT
0%
Dependence Risk
No withdrawal, no sedation, no amnesia
2009
Approved in Russia
Prescription drug for GAD since 2009
7
Amino Acids
Tuftsin analog + Pro-Gly-Pro extension
Mechanism of Action
How Selank Works
Multi-pathway anxiolytic and nootropic — reduces anxiety without sedation, while simultaneously enhancing cognition
GABA
GABAergic System — Primary
Allosterically modulates GABA-A receptors without binding to benzodiazepine sites — reducing anxiety through calming neurotransmission while preserving cognitive function and avoiding sedation or dependence
BDNF
BDNF Pathway — Nootropic
Upregulates brain-derived neurotrophic factor (BDNF) expression, supporting synaptic plasticity and memory consolidation — the mechanism behind Selank’s unique anxiolytic + cognitive enhancing dual effect
ENK
Enkephalin System — Stress Relief
Inhibits enzymes that degrade enkephalins (endogenous opioid peptides), prolonging the body’s natural stress-relief signals and modulating emotional responses through the endogenous opioid system
Selank vs Benzodiazepines
Anxiety Relief Without the Tradeoffs
Clinical trials show comparable anxiolytic efficacy to medazepam — but Selank adds antiasthenic and psychostimulatory effects, with none of the cognitive impairment or dependence
↓ Anxiety
Selank ✓ Benzos ✓
↑ Cognition
Selank ✓ Benzos ✗
0%
Sedation (Selank)
0%
Dependence (Selank)
Clinical Research
What Research Has Shown
Human RCT vs medazepam (benzodiazepine) in 62 GAD patients — 14-day treatment period
0%
Key Safety Outcome
Dependence, Sedation, or Cognitive Impairment
62 patients · 14-day RCT · Hamilton, Zung & CGI scales · Zozulia et al. 2008
Anxiolytic Efficacy vs Medazepam
Zozulia et al. 2008 (PMID 18454096) — efficacy comparable, safety profile superior
Key Clinical Outcomes
Side Effects (Clinical Trials)
Breaks down into natural amino acids — exceptionally safe metabolic profile.
🧠
Research Applications
Multi-system benefits from clinical and preclinical research
Calm
Anxiety Relief
85% efficacy in GAD — comparable to benzodiazepines without sedation or dependence risk
Sharp
Cognitive Enhancement
BDNF upregulation supports memory, attention, and learning — unlike benzodiazepines which impair cognition
BDNF
Neuroprotection
Upregulates brain-derived neurotrophic factor, supporting neuroplasticity and long-term brain health
IL-6
Immune Modulation
Derived from tuftsin — inherits immunomodulatory properties including IL-6 and cytokine regulation
📖 Nootropic Effects
Cognitive Enhancement
BDNF upregulation and neurotransmitter normalization support multiple cognitive domains
Memory consolidation↑ Enhanced
Attention and focus↑ Improved
Learning capacity↑ Facilitated
Mental fatigue↓ Reduced (antiasthenic)
Dual action: Unlike typical anxiolytics that cloud thinking, Selank is simultaneously anxiolytic and psychostimulatory — reducing anxiety while sharpening mental performance.
⚖ Selank vs Benzos
Head-to-Head Comparison
RCT data + mechanistic profile vs medazepam
Anxiolytic efficacyBoth comparable
Cognitive functionSelank: Enhanced ✓
SedationSelank: 0% ✓
Physical dependenceSelank: 0% ✓
Antiasthenic effectSelank only ✓
Immune & Safety
Tuftsin-Derived Immunomodulation
Inherited from tuftsin parent compound — natural immunomodulatory properties
IL-6 modulationConfirmed
Cytokine regulationObserved
Metabolic breakdownNatural amino acids
Serious adverse events0 reported
Safety basis: Selank breaks down into natural amino acids, giving it an exceptionally favorable metabolic safety profile.
Compound Specifications
Compound Information
Technical specifications for Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro)
Molecular Profile
What Is Selank?
TypeSynthetic heptapeptide
CAS Number129954-34-3
Molecular FormulaC33H57N11O9
Molecular Weight751.9 g/mol
Amino Acids7 residues
SequenceThr-Lys-Pro-Arg-Pro-Gly-Pro
Parent compoundTuftsin (+ Pro-Gly-Pro for stability)
Storage Requirements
Stability Information
Lyophilized (powder)−20°C, protect from light
Reconstituted2–8°C, up to 4 weeks
Nasal spray (0.15%)2–8°C, 30 days after opening
Approved formulation0.15% intranasal drops (Russia)
Purity (EON standard)>99% HPLC + MS verified
Approved Russia 2009Research in US
Regulatory Status
Development & Approval
DeveloperRussian Academy of Sciences
CollaboratorV.V. Zakusov Institute
ApprovalRussia (2009) + Ukraine
IndicationGeneralized Anxiety Disorder
US StatusNot FDA-approved
Rx formulation (RU)0.15% nasal drops
Scientific Literature
Key Publications
Clinical and mechanistic research on Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro)
- Zozulia AA, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. PMID: 18454096.
- Semenova TP, et al. Anxiolytic and nootropic effects of Selank in open field and radial maze tests. Bull Exp Biol Med. 2016. PMC4757669.
- Kasian A, et al. BDNF upregulation by Selank in experimental neurological models. Neuropeptides. 2019. PMID: 31625062.
- Neyasov AA, et al. Enkephalin metabolism regulation by Selank. Peptides. 2001. PMID: 11550013.
- Immunomodulatory effects of Selank on cytokine expression. Biochemistry. 2020. PMID: 32621722.
Common Questions
Frequently Asked Questions
Common questions about Selank research
Selank is a synthetic heptapeptide (7 amino acids: Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It’s derived from tuftsin, a naturally occurring immunomodulatory tetrapeptide found in the Fc region of immunoglobulin G (IgG). The C-terminus was extended with Pro-Gly-Pro to enhance metabolic stability and prolong duration. Selank has been approved in Russia and Ukraine since 2009 as a prescription drug for generalized anxiety disorder.
Both Selank and benzodiazepines reduce anxiety through the GABAergic system, but via different mechanisms. Benzodiazepines directly bind to benzodiazepine sites on GABA-A receptors, causing sedation, memory impairment, and physical dependence. Selank allosterically modulates GABA-A receptors without these side effects. Clinical trials show comparable anxiolytic efficacy, but Selank additionally produces antiasthenic (anti-fatigue) and psychostimulatory effects — enhancing cognition rather than impairing it.
A key randomized controlled trial compared intranasal Selank (30 patients) to oral medazepam (32 patients) in 62 patients with generalized anxiety disorder and neurasthenia over 14 days. Both showed similar anxiolytic effects on Hamilton, Zung, and CGI psychometric scales (85% vs 83% efficacy). Crucially, Selank also showed antiasthenic and psychostimulatory effects not seen with medazepam, while producing no sedation, no dependence, and no cognitive impairment.
Selank upregulates BDNF (brain-derived neurotrophic factor), which supports synaptic plasticity, memory consolidation, and learning. It also normalizes serotonin and dopamine levels while inhibiting enkephalin-degrading enzymes. Together, these mechanisms produce both anxiety reduction and cognitive enhancement — a profile distinct from all benzodiazepines, which universally impair cognition. This dual action makes Selank unique among anxiolytic compounds.
Yes. Selank is approved in Russia (since 2009) and Ukraine as a prescription drug for generalized anxiety disorder, available as 0.15% nasal drops. It is not FDA-approved in the United States and is classified as a research compound in most Western countries. Clinical use in Russia for over 15 years provides a substantial real-world safety data set.
Published research on this compound is available through PubMed and other scientific databases.
Certificate of Analysis
| Analysis Date: | Available on request |
| Lot Number: | Batch-specific |
| Purity: | >99% (HPLC) |
Third-Party Testing
- ✓ Identity verification (Mass Spectrometry)
- ✓ Purity analysis (HPLC)
- ✓ Sterility testing
- ✓ Endotoxin screening
Storage Conditions
- Lyophilized: Store at -20°C, protected from light
- Reconstituted: Store at 2-8°C, use within 30 days
- Stability: 24 months from manufacture date when stored properly
Handling Guidelines
- Use sterile technique when reconstituting
- Allow vial to reach room temperature before opening
- Reconstitute with bacteriostatic water or sterile saline
- Avoid repeated freeze-thaw cycles
RESEARCH INSIGHTS
3D Structure
Selank
This compound has been extensively studied in peer-reviewed literature. Eon Peptides provides this product exclusively for legitimate in-vitro research and analytical applications.
- • High-purity research compound
- • Full analytical documentation included
- • Third-party verification available
PRODUCT SPECIFICATIONS
LOT DATA
| Lot Number | Assigned on shipment |
| Verified Purity | >99% |
| Quantity | 5mg |
MOLECULAR DATA
| Molecular Formula | Available on request |
| Form | Lyophilized Powder |
| Appearance | White to off-white powder |
Researchers who studied this also studied...
Related products
These products are intended for laboratory research purposes only, and are not for human or animal consumption.